13 research outputs found
The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review
Thin-slices multi-detector computed tomography (MDCT) plays a key role in the differential diagnosis of interstitial lung disease (ILD). However, thin-slices MDCT has a limited ability to detect active inflammation, which is an important target of newly developed ILD drug therapy. Magnetic resonance imaging (MRI), thanks to its multi-parameter capability, provides better tissue characterisation than thin-slices MDCT.Our aim was to summarise the current status of MRI applications in ILD and to propose an ILD-MRI protocol. A systematic literature search was conducted for relevant studies on chest MRI in patients with ILD.We retrieved 1246 papers of which 55 original papers were selected for the review. We identified 24 studies comparing image quality of thin-slices MDCT and MRI using several MRI sequences. These studies described new MRI sequences to assess ILD parenchymal abnormalities, such as honeycombing, reticulation and ground-glass opacity. Thin-slices MDCT remains superior to MRI for morphological imaging. However, recent studies with ultra-short echo-time MRI showed image quality comparable to thin-slices MDCT. Several studies demonstrated the added value of chest MRI by using functional imaging, especially to detect and quantify inflammatory changes.We concluded that chest MRI could play a role in ILD patients to differentiate inflammatory and fibrotic changes and to assess efficacy of new ILD drugs
Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences
The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported
by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on
18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based
researchers who signed it in the short time span from 20 September to 6 October 2016
Burnout among surgeons before and during the SARS-CoV-2 pandemic: an international survey
Background: SARS-CoV-2 pandemic has had many significant impacts within the surgical realm, and surgeons have been obligated to reconsider almost every aspect of daily clinical practice. Methods: This is a cross-sectional study reported in compliance with the CHERRIES guidelines and conducted through an online platform from June 14th to July 15th, 2020. The primary outcome was the burden of burnout during the pandemic indicated by the validated Shirom-Melamed Burnout Measure. Results: Nine hundred fifty-four surgeons completed the survey. The median length of practice was 10 years; 78.2% included were male with a median age of 37 years old, 39.5% were consultants, 68.9% were general surgeons, and 55.7% were affiliated with an academic institution. Overall, there was a significant increase in the mean burnout score during the pandemic; longer years of practice and older age were significantly associated with less burnout. There were significant reductions in the median number of outpatient visits, operated cases, on-call hours, emergency visits, and research work, so, 48.2% of respondents felt that the training resources were insufficient. The majority (81.3%) of respondents reported that their hospitals were included in the management of COVID-19, 66.5% felt their roles had been minimized; 41% were asked to assist in non-surgical medical practices, and 37.6% of respondents were included in COVID-19 management. Conclusions: There was a significant burnout among trainees. Almost all aspects of clinical and research activities were affected with a significant reduction in the volume of research, outpatient clinic visits, surgical procedures, on-call hours, and emergency cases hindering the training. Trial registration: The study was registered on clicaltrials.gov "NCT04433286" on 16/06/2020
Catálogo Taxonômico da Fauna do Brasil: setting the baseline knowledge on the animal diversity in Brazil
The limited temporal completeness and taxonomic accuracy of species lists, made available in a traditional manner in scientific publications, has always represented a problem. These lists are invariably limited to a few taxonomic groups and do not represent up-to-date knowledge of all species and classifications. In this context, the Brazilian megadiverse fauna is no exception, and the Catálogo Taxonômico da Fauna do Brasil (CTFB) (http://fauna.jbrj.gov.br/), made public in 2015, represents a database on biodiversity anchored on a list of valid and expertly recognized scientific names of animals in Brazil. The CTFB is updated in near real time by a team of more than 800 specialists. By January 1, 2024, the CTFB compiled 133,691 nominal species, with 125,138 that were considered valid. Most of the valid species were arthropods (82.3%, with more than 102,000 species) and chordates (7.69%, with over 11,000 species). These taxa were followed by a cluster composed of Mollusca (3,567 species), Platyhelminthes (2,292 species), Annelida (1,833 species), and Nematoda (1,447 species). All remaining groups had less than 1,000 species reported in Brazil, with Cnidaria (831 species), Porifera (628 species), Rotifera (606 species), and Bryozoa (520 species) representing those with more than 500 species. Analysis of the CTFB database can facilitate and direct efforts towards the discovery of new species in Brazil, but it is also fundamental in providing the best available list of valid nominal species to users, including those in science, health, conservation efforts, and any initiative involving animals. The importance of the CTFB is evidenced by the elevated number of citations in the scientific literature in diverse areas of biology, law, anthropology, education, forensic science, and veterinary science, among others
Automatic Lung Segmentation in CT Images with Accurate Handling of the Hilar Region
A fully automated and three-dimensional (3D) segmentation method for the identification of the pulmonary parenchyma in thorax X-ray computed tomography (CT) datasets is proposed. It is meant to be used as pre-processing step in the computer-assisted detection (CAD) system for malignant lung nodule detection that is being developed by the Medical Applications in a Grid Infrastructure Connection (MAGIC-5) Project. In this new approach the segmentation of the external airways (trachea and bronchi), is obtained by 3D region growing with wavefront simulation and suitable stop conditions, thus allowing an accurate handling of the hilar region, notoriously difficult to be segmented. Particular attention was also devoted to checking and solving the problem of the apparent ‘fusion’ between the lungs, caused by partial-volume effects, while 3D morphology operations ensure the accurate inclusion of all the nodules (internal, pleural, and vascular) in the segmented volume. The new algorithm was initially developed and tested on a dataset of 130 CT scans from the Italung-CT trial, and was then applied to the ANODE09-competition images (55 scans) and to the LIDC database (84 scans), giving very satisfactory results. In particular, the lung contour was adequately located in 96% of the CT scans, with incorrect segmentation of the external airways in the remaining cases. Segmentation metrics were calculated that quantitatively express the consistency between automatic and manual segmentations: the mean overlap degree of the segmentation masks is 0.96 ± 0.02, and the mean and the maximum distance between the mask borders (averaged on the whole dataset) are 0.74 ± 0.05 and 4.5 ± 1.5, respectively, which confirms that the automatic segmentations quite correctly reproduce the borders traced by the radiologist. Moreover, no tissue containing internal and pleural nodules was removed in the segmentation process, so that this method proved to be fit for the use in the framework of a CAD system. Finally, in the comparison with a two-dimensional segmentation procedure, inter-slice smoothness was calculated, showing that the masks created by the 3D algorithm are significantly smoother than those calculated by the 2D-only procedure
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.
To the Editor:
Nonvalvular atrial fibrillation (NVAF) is the most common sustained arrhythmia encountered in clinical practice and is associated with a 5-fold increased risk for stroke (1).
Moreover, patients with NVAF often suffer from atherosclerotic complications such as acute myocardial infarction (AMI) (2). Peripheral artery disease (PAD) is an established marker of systemic atherosclerosis but its prevalence in NVAF is still unclear. We reasoned that inclusion of ankle-brachial index (ABI), which is an established tool for diagnosis of PAD (3), in the CHA2DS2-VASc (4) score would better define the prevalence of vascular disease.
To address this issue, the Italian Society of Internal Medicine (SIMI) established an Italian registry documenting ABI in NVAF patients.
The Atrial Fibrillation Registry for the ARAPACIS (Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study) study is an independent research project involving all Regional Councils of SIMI. The first objective of the study was to estimate the prevalence of ABI 640.90 in NVAF patients.
Consecutive patients with NVAF referred to internal medicine wards were eligible for the enrollment. Enrollment started in October 2010 and continued until October 30, 2012. Patients were enrolled if they were 18 years or older and had a diagnosis of NVAF, recording during the qualifying admission/consultation or in the preceding 12 months, and if it was possible to obtain the ABI measurement. Exclusion criteria included the following: acquired or congenital valvular AF, active cancer, disease with life expectancy <3 years, hyperthyroidism and pregnancy.
We initially planned to include 3,000 patients. The Data and Safety Monitoring Board (Online Appendix) decided to perform an interim analysis to assess the prevalence of ABI in the enrolled populations\u2014as a higher than expected prevalence of low ABI was detected\u2014and decided to interrupt the patients' enrollment. The sample size was amended as follows: a sample of 2,027 patients leads to the expected prevalence of 21% with a 95% confidence interval width of 3.5% (StataCorp LP, College Station, Texas).
Among the 2,027 NVAF patients included in the study, hypertension was detected in 83%, diabetes mellitus in 23%, dyslipidemia in 39%, metabolic syndrome in 29%, and smoking in 15%. At least 1 atherosclerotic risk factor was detected in 90% of patients.
The NVAF population was at high risk for stroke, with only 18% having a CHA2DS2-VASc score of 0 to 1, while 82% had a risk 652. Despite this, 16% were untreated with any antithrombotic drug, 19% were treated with antiplatelet drugs (APs), and 61% with oral anticoagulants (OAC); 4% of patients were treated with both APs and OAC.
Among the AF population, 428 patients (21%) had ABI 640.90 compared with 1,381 patients, who had an ABI of 0.91 to 1.39 (69%); 204 patients (10%) had ABI 651.40 (Fig. 1). ABI recorded only in 1 leg was excluded from the analysis (n = 14). ABI 640.90 progressively increased from paroxysmal to permanent NVAF (18%, 21%, 24%; p = 0.0315).
Figure 1.
ABI Distribution of Any Category and CHA2DS2-VASc Score Including ABI 640.90
C = congestive heart failure (or left ventricular systolic dysfunction) (Points: 1), H = hypertension (Points: 1), A2 = Age 6575 years (Points: 2), D = diabetes mellitus (Points: 1), S2 = prior stroke or transient ischemic attack or thromboembolism (Points: 2); V = vascular disease (previous acute myocardial infarction, peripheral arterial disease, or aortic plaque) (Points: 1); A = age 65 to 74 years (Points: 1); Sc = sex category (female) (Points: 1). ABI = ankle brachial index.
Figure optionsDownload full-size imageDownload high-quality image (447 K)Download as PowerPoint slide
NVAF patients with ABI 640.90 were more likely to be hypertensive (88% vs. 82%; p = 0.032), diabetic (34% vs. 20%; p 0.90 (93% vs. 82%; p < 0.0001).
Logistic regression analysis demonstrated that ABI 640.90 was significantly associated with a smoking habit (odds ratio [OR]: 1.99; 95% confidence interval [CI]: 1.48 to 2.66; p < 0.0001), diabetes (OR: 1.93; 95% CI: 1.51 to 2.46; p < 0.0001), age class 65 to 74 years (OR: 2.05; 95% CI: 1.40 to 3.07; p < 0.0001), age class 6575 years (OR: 3.12; 95% CI: 2.16 to 4.61; p < 0.0001), and history of previous transient ischemic attack/stroke (OR: 1.64; 95% CI: 1.20 to 2.24; p = 0.002).
Vascular disease, as assessed by the history elements of CHA2DS2VASc score, was recorded in 17.3% of patients; inclusion of ABI 640.90 in the definition of vascular disease yielded a total prevalence of 33%. A higher prevalence of vascular disease was detected if ABI 640.90 was included in the CHA2DS2VASc score (Fig. 1). CHA2DS2VASc including ABI 640.90 was more associated with previous stroke (43%; OR: 1.85; 95% CI: 1.41 to 2.44; p < 0.0001) compared to CHA2DS2VASc with ABI 0.91 to 1.39 (23%; OR: 1.52; 95% CI: 1.10 to 2.11; p = 0.0117).
To the best of our knowledge, there is no large-scale study that specifically examined the prevalence of ABI 640.90 in NVAF. In our population, 21% had ABI 640.90 indicating that NVAF is often associated with systemic atherosclerosis.
The CHADS2 has been recently refined with the CHA2DS2-VASc score, which includes vascular disease as documented by a history of AMI, symptomatic PAD, or detection of atherosclerotic plaque in the aortic arch (4).
Comparison of vascular prevalence as assessed by CHA2DS2-VASc score and/or ABI 640.90 is of interest to define the potentially positive impact of measuring ABI in the management of NVAF patients. Inclusion of ABI 640.90 in the definition of vascular disease greatly increased the prevalence of vascular disease, which increased from 17.3% (based on history alone) to 33% (based on ABI) in the entire population. If ABI 640.90 was encompassed in the definition of vascular disease of CHA2DS2-VASc score the prevalence of vascular disease increased in every risk class.
Inclusion of ABI 640.90 in the CHA2DS2-VASc score allowed us to better define the risk profile of NVAF patients with an up-grading of the risk score in each CHA2DS2-VASc score category. This may have important therapeutic implications if the new score could be tested prospectively, as a higher number of NVAF patients would potentially be candidates for an anticoagulant treatment by measuring ABI. A prospective study is, therefore, necessary to validate the risk score of this new definition of vascular disease.
In conclusion, this study provides the first evidence that one-fifth of NVAF patients had an ABI 640.90, indicating that it may represent a simple and cheap method to better define the prevalence of vascular disease in NVAF
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: Implications for risk and therapy
To the Editor: Nonvalvular atrial fibrillation (NVAF) is the most
common sustained arrhythmia encountered in clinical practice and
is associated with a 5-fold increased risk for stroke (1).
Moreover, patients with NVAF often suffer from atherosclerotic
complications such as acute myocardial infarction (AMI) (2).
Peripheral artery disease (PAD) is an established marker of systemic
atherosclerosis but its prevalence in NVAF is still unclear. We
reasoned that inclusion of ankle-brachial index (ABI), which is an
established tool for diagnosis of PAD (3), in the CHA2DS2-VASc
(4) score would better define the prevalence of vascular disease.
Toaddress this issue, the ItalianSociety of InternalMedicine (SIMI)
established an Italian registry documenting ABI inNVAF patients.
The Atrial Fibrillation Registry for the ARAPACIS (Ankle-
brachial Index Prevalence Assessment: Collaborative Italian Study)
study is an independent research project involving all Regional
Councils of SIMI. The first objective of the study was to estimate
the prevalence of ABI 0.90 in NVAF patients.
Consecutive patients with NVAF referred to internal medicine
wards were eligible for the enrollment. Enrollment started in
October 2010 and continued until October 30, 2012. Patients were
enrolled if they were 18 years or older and had a diagnosis of
NVAF, recording during the qualifying admission/consultation or
in the preceding 12 months, and if it was possible to obtain the
ABI measurement. Exclusion criteria included the following:
acquired or congenital valvular AF, active cancer, disease with life
expectancy <3 years, hyperthyroidism and pregnancy.
We initially planned to include 3,000 patients. The Data and
Safety Monitoring Board (Online Appendix) decided to perform an
interim analysis to assess the prevalence of ABI in the enrolled
populationsdas a higher than expected prevalence of low ABI was
detecteddand decided to interrupt the patients’ enrollment. The
sample size was amended as follows: a sample of 2,027 patients leads
to the expected prevalence of 21% with a 95% confidence interval
width of 3.5% (StataCorp LP, College Station, Texas).
Among the 2,027 NVAF patients included in the study, hyper-
tension was detected in 83%, diabetes mellitus in 23%, dyslipidemia
in 39%, metabolic syndrome in 29%, and smoking in 15%. At least 1
atherosclerotic risk factor was detected in 90% of patients.
The NVAF population was at high risk for stroke, with only
18% having a CHA2DS2-VASc score of 0 to 1, while 82% had
a risk 2. Despite this, 16% were untreated with any antith-
rombotic drug, 19% were treated with antiplatelet drugs (APs), and
61% with oral anticoagulants (OAC); 4% of patients were treated
with both APs and OAC.
Among the AF population, 428 patients (21%) had ABI 0.90
(69%); 204 patients (10%) had ABI 1.40 (Fig. 1). ABI recorded
only in 1 leg was excluded from the analysis (n ¼ 14). ABI 0.90
progressively increased from paroxysmal to permanent NVAF (18%,
tensive (88% vs. 82%; p ¼ 0.032), diabetic (34% vs. 20%; p <
0.0001), or smokers (20% vs. 14%; p ¼ 0.0008), or to have experi-
enced transient ischemic attack or stroke (17% vs. 10%; p < 0.001).
21%, 24%; p ¼ 0.0315).
NVAF patients with ABI 0.90 were more likely to be hyper-
NVAF patients with ABI 0.90 had a higher percentage of
CHA2DS2-VASc score 2 compared with those with ABI >0.90
(93% vs. 82%; p < 0.0001).
significantly associated with a smoking habit (odds ratio [OR]:
1.99; 95% confidence interval [CI]: 1.48 to 2.66; p < 0.0001),
diabetes (OR: 1.93; 95% CI: 1.51 to 2.46; p < 0.0001), age class 65
to 74 years (OR: 2.05; 95% CI: 1.40 to 3.07; p < 0.0001), age
Logistic regression analysis demonstrated that ABI 0.90 was
class 75 years (OR: 3.12; 95% CI: 2.16 to 4.61; p < 0.0001),
and history of previous transient ischemic attack/stroke (OR: 1.64;
95% CI: 1.20 to 2.24; p ¼ 0.002).
Vascular disease, as assessed by the history elements of
CHA2DS2VASc score, was recorded in 17.3% of patients; inclu-
sion of ABI 0.90 in the definition of vascular disease yielded
a total prevalence of 33%. A higher prevalence of vascular disease
was detected if ABI 0.90 was included in the CHA2DS2VASc
score (Fig. 1). CHA2DS2VASc including ABI 0.90 was more
associated with previous stroke (43%; OR: 1.85; 95% CI: 1.41 to
2.44; p < 0.0001) compared to CHA2DS2VASc with ABI 0.91 to
1.39 (23%; OR: 1.52; 95% CI: 1.10 to 2.11; p ¼ 0.0117).
To the best of our knowledge, there is no large-scale study that
specifically examined the prevalence of ABI 0.90 in NVAF. In
our population, 21% had ABI 0.90 indicating that NVAF is
often associated with systemic atherosclerosis.
The CHADS2 has been recently refined with the CHA2DS2-
VASc score, which includes vascular disease as documented by
a history of AMI, symptomatic PAD, or detection of atheroscle-
rotic plaque in the aortic arch (4).
Comparison of vascular prevalence as assessed by CHA2DS2-
NVAF patients. Inclusion of ABI 0.90 in the definition of
vascular disease greatly increased the prevalence of vascular disease,
which increased from 17.3% (based on history alone) to 33% (based
compared with 1,381 patients, who had an ABI of 0.91 to 1.39
to better define the risk profile ofNVAFpatients with an up-grading
of the risk score in each CHA2DS2-VASc score category. This may
have important therapeutic implications if the new score could be
tested prospectively, as a higher number of NVAF patients would
on ABI) in the entire population. If ABI 0.90 was encompassed
in the definition of vascular disease of CHA2DS2-VASc score the
prevalence of vascular disease increased in every risk class.
Inclusion of ABI0.90 in theCHA2DS2-VASc score allowed us
VASc score and/or ABI 0.90 is of interest to define the poten-
tially positive impact of measuring ABI in the management of potentially be candidates for an anticoagulant treatment by
measuring ABI. A prospective study is, therefore, necessary to
validate the risk score of this new definition of vascular disease.
In conclusion, this study provides the first evidence that one-fifth
of NVAF patients had an ABI 0.90, indicating that it may
represent a simple and cheap method to better define the prevalence
of vascular disease in NVAF
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: Implications for risk and therapy
To the Editor: Nonvalvular atrial fibrillation (NVAF) is the most
common sustained arrhythmia encountered in clinical practice and
is associated with a 5-fold increased risk for stroke (1).
Moreover, patients with NVAF often suffer from atherosclerotic
complications such as acute myocardial infarction (AMI) (2).
Peripheral artery disease (PAD) is an established marker of systemic
atherosclerosis but its prevalence in NVAF is still unclear. We
reasoned that inclusion of ankle-brachial index (ABI), which is an
established tool for diagnosis of PAD (3), in the CHA2DS2-VASc
(4) score would better define the prevalence of vascular disease.
Toaddress this issue, the ItalianSociety of InternalMedicine (SIMI)
established an Italian registry documenting ABI inNVAF patients.
The Atrial Fibrillation Registry for the ARAPACIS (Ankle-
brachial Index Prevalence Assessment: Collaborative Italian Study)
study is an independent research project involving all Regional
Councils of SIMI. The first objective of the study was to estimate
the prevalence of ABI 0.90 in NVAF patients.
Consecutive patients with NVAF referred to internal medicine
wards were eligible for the enrollment. Enrollment started in
October 2010 and continued until October 30, 2012. Patients were
enrolled if they were 18 years or older and had a diagnosis of
NVAF, recording during the qualifying admission/consultation or
in the preceding 12 months, and if it was possible to obtain the
ABI measurement. Exclusion criteria included the following:
acquired or congenital valvular AF, active cancer, disease with life
expectancy <3 years, hyperthyroidism and pregnancy.
We initially planned to include 3,000 patients. The Data and
Safety Monitoring Board (Online Appendix) decided to perform an
interim analysis to assess the prevalence of ABI in the enrolled
populationsdas a higher than expected prevalence of low ABI was
detecteddand decided to interrupt the patients’ enrollment. The
sample size was amended as follows: a sample of 2,027 patients leads
to the expected prevalence of 21% with a 95% confidence interval
width of 3.5% (StataCorp LP, College Station, Texas).
Among the 2,027 NVAF patients included in the study, hyper-
tension was detected in 83%, diabetes mellitus in 23%, dyslipidemia
in 39%, metabolic syndrome in 29%, and smoking in 15%. At least 1
atherosclerotic risk factor was detected in 90% of patients.
The NVAF population was at high risk for stroke, with only
18% having a CHA2DS2-VASc score of 0 to 1, while 82% had
a risk 2. Despite this, 16% were untreated with any antith-
rombotic drug, 19% were treated with antiplatelet drugs (APs), and
61% with oral anticoagulants (OAC); 4% of patients were treated
with both APs and OAC.
Among the AF population, 428 patients (21%) had ABI 0.90
(69%); 204 patients (10%) had ABI 1.40 (Fig. 1). ABI recorded
only in 1 leg was excluded from the analysis (n 1⁄4 14). ABI 0.90
progressively increased from paroxysmal to permanent NVAF (18%,
tensive (88% vs. 82%; p 1⁄4 0.032), diabetic (34% vs. 20%; p <
0.0001), or smokers (20% vs. 14%; p 1⁄4 0.0008), or to have experi-
enced transient ischemic attack or stroke (17% vs. 10%; p < 0.001).
21%, 24%; p 1⁄4 0.0315).
NVAF patients with ABI 0.90 were more likely to be hyper-
NVAF patients with ABI 0.90 had a higher percentage of
CHA2DS2-VASc score 2 compared with those with ABI >0.90
(93% vs. 82%; p < 0.0001).
significantly associated with a smoking habit (odds ratio [OR]:
1.99; 95% confidence interval [CI]: 1.48 to 2.66; p < 0.0001),
diabetes (OR: 1.93; 95% CI: 1.51 to 2.46; p < 0.0001), age class 65
to 74 years (OR: 2.05; 95% CI: 1.40 to 3.07; p < 0.0001), age
Logistic regression analysis demonstrated that ABI 0.90 was
class 75 years (OR: 3.12; 95% CI: 2.16 to 4.61; p < 0.0001),
and history of previous transient ischemic attack/stroke (OR: 1.64;
95% CI: 1.20 to 2.24; p 1⁄4 0.002).
Vascular disease, as assessed by the history elements of
CHA2DS2VASc score, was recorded in 17.3% of patients; inclu-
sion of ABI 0.90 in the definition of vascular disease yielded
a total prevalence of 33%. A higher prevalence of vascular disease
was detected if ABI 0.90 was included in the CHA2DS2VASc
score (Fig. 1). CHA2DS2VASc including ABI 0.90 was more
associated with previous stroke (43%; OR: 1.85; 95% CI: 1.41 to
2.44; p < 0.0001) compared to CHA2DS2VASc with ABI 0.91 to
1.39 (23%; OR: 1.52; 95% CI: 1.10 to 2.11; p 1⁄4 0.0117).
To the best of our knowledge, there is no large-scale study that
specifically examined the prevalence of ABI 0.90 in NVAF. In
our population, 21% had ABI 0.90 indicating that NVAF is
often associated with systemic atherosclerosis.
The CHADS2 has been recently refined with the CHA2DS2-
VASc score, which includes vascular disease as documented by
a history of AMI, symptomatic PAD, or detection of atheroscle-
rotic plaque in the aortic arch (4).
Comparison of vascular prevalence as assessed by CHA2DS2-
NVAF patients. Inclusion of ABI 0.90 in the definition of
vascular disease greatly increased the prevalence of vascular disease,
which increased from 17.3% (based on history alone) to 33% (based
compared with 1,381 patients, who had an ABI of 0.91 to 1.39
to better define the risk profile ofNVAFpatients with an up-grading
of the risk score in each CHA2DS2-VASc score category. This may
have important therapeutic implications if the new score could be
tested prospectively, as a higher number of NVAF patients would
on ABI) in the entire population. If ABI 0.90 was encompassed
in the definition of vascular disease of CHA2DS2-VASc score the
prevalence of vascular disease increased in every risk class.
Inclusion of ABI0.90 in theCHA2DS2-VASc score allowed us
VASc score and/or ABI 0.90 is of interest to define the poten-
tially positive impact of measuring ABI in the management of potentially be candidates for an anticoagulant treatment by
measuring ABI. A prospective study is, therefore, necessary to
validate the risk score of this new definition of vascular disease.
In conclusion, this study provides the first evidence that one-fifth
of NVAF patients had an ABI 0.90, indicating that it may
represent a simple and cheap method to better define the prevalence
of vascular disease in NVAF
SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 days of surgery. SARS-CoV-2 diagnosis was defined as peri-operative (7 days before to 30 days after surgery); recent (1-6 weeks before surgery); previous (>= 7 weeks before surgery); or none. Information on prophylaxis regimens or pre-operative anti-coagulation for baseline comorbidities was not available. Postoperative venous thromboembolism rate was 0.5% (666/123,591) in patients without SARS-CoV-2; 2.2% (50/2317) in patients with peri-operative SARS-CoV-2; 1.6% (15/953) in patients with recent SARS-CoV-2; and 1.0% (11/1148) in patients with previous SARS-CoV-2. After adjustment for confounding factors, patients with peri-operative (adjusted odds ratio 1.5 (95%CI 1.1-2.0)) and recent SARS-CoV-2 (1.9 (95%CI 1.2-3.3)) remained at higher risk of venous thromboembolism, with a borderline finding in previous SARS-CoV-2 (1.7 (95%CI 0.9-3.0)). Overall, venous thromboembolism was independently associated with 30-day mortality (5.4 (95%CI 4.3-6.7)). In patients with SARS-CoV-2, mortality without venous thromboembolism was 7.4% (319/4342) and with venous thromboembolism was 40.8% (31/76). Patients undergoing surgery with peri-operative or recent SARS-CoV-2 appear to be at increased risk of postoperative venous thromboembolism compared with patients with no history of SARS-CoV-2 infection. Optimal venous thromboembolism prophylaxis and treatment are unknown in this cohort of patients, and these data should be interpreted accordingly